Innovative ProceduresESTA confirmed the limited launch of Preservé in the US and announced expectations for its minimally invasive platform to generate at least $30M in revenue in 2026, with continued TAM expansion on both a dollar and procedure basis.
Market Share GrowthESTA is poised to continue taking share in the US market and growing at a higher rate than its expected commercial investment.
Profitability And MarginsESTA's gross margin increased by 620 bps Y/Y and its adjusted EBITDA margin increased by 1,960 bps Y/Y, turning positive for the first time.